Novartis and Israeli firm Compugen have entered into an agreement forthe Swiss firm to use the latter's technology services to accelerate identification of drug targets based on the analysis of fundamental gene and protein data. Under the deal, Novartis will utilize Compugen's LEADS computational biology platform to create a complete database that will detail gene expression "at the miniscule level of RNA."
According to Paul Herrling, head of global research for Novartis Pharma, "at a time when biotechs and pharmas are adapting to leverage the therapeutic potential of the human genome, Novartis aims to set the standard for how the pharmaceutical industry can swiftly translate the promise of this new science into meaningful therapies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze